RE: Myles Tweet: Updated Avacta18 Aug 2021 17:07
Myles on supply and demand
'Shipment of Avacta’s AffiDX SARS-CoV-2 LFT began in the first week of August. Pre-orders of the LFT from
early July ensured that the test was sold out several weeks before first shipment. We have been informed that
delivery recommences next week. Whilst the Company has not provided details of production levels to date, we
estimate that it will deliver one to two million tests in August. Currently, the production output is entirely down
to a single manufacturing partner, namely Global Access Health (‘GAH’) (formally called Global Access
Diagnostics). Avacta’s second UK-based manufacturing partner, Abingdon Health, is set to come online in the
next several weeks. We believe that once both GAH and Abingdon are manufacturing the AffiDX LFT at their
contracted full capacity, Avacta’s output will be in the region of four to five million units per month.
Given that demand is indisputably already outstripping supply, we believe that Avacta will also mobilise an
international manufacturer (based in Mainland Europe, in our view) in the coming weeks. [Eight weeks ago,
management stated in a presentation that the tech transfer to said manufacturing partner that was already
underway, would take 6-8 weeks.] This unnamed manufacturer will have the capacity to scale to 30 million units
per month.
Management has stated that gross profit per LFT sold will be in the region of €1 to €2. I